Scholarlink

<p>Dysregulated levels of pro-inflammatory cytokines such as interleukin (IL)-23 have been linked to multiple inflammatory diseases, including psoriatic arthritis (PsA) and ankylosing spondylitis. This systematic review explored the effect of IL-12 and/or IL-23 inhibitors on the aetiology of axial PsA (axPsA) and axial spondyloarthritis (axSpA). We conducted a literature review of published articles up to June 2023. The outcomes assessed included Ankylosing Spondylitis Disease Activity Score, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), BASDAI-50, and modified BASDAI. Given the heterogeneity of study populations, designs, and outcome measures of the included studies, we performed a narrative synthesis. The data from the limited literature did not find any efficacy of IL-12 and/or IL-23 inhibitors for the management of axSpA, except for one observational study. However, reported data showed improvements in BASDAI, modified BASDAI, and Ankylosing Spondylitis Disease Activity Score for patients with axPsA. Limited and heterogeneous data currently leaves the effectiveness of IL-12 and/or IL-23 inhibitors for axSpA inconclusive. Yet, improvements in disease activity scores for patients with axPsA hint at the potential of IL-12 and/or IL-23 inhibitors in managing this condition. More extensive studies with larger samples are needed to definitively confirm the role of IL-12 and/or IL-23 inhibitors in axSpA and PsA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of IL-12 and/or IL-23 inhibitors in axial spondyloarthritis and axial psoriatic arthritis: a systematic review

  • 期刊论文

  • 发表日期：

    2025年7月18日

查看全文
  • Shamma Ahmad Al Nokhatha,
  • Sinead Maguire,
  • Wesam Gouda,
  • Khalid A. Alnaqbi

摘要

Dysregulated levels of pro-inflammatory cytokines such as interleukin (IL)-23 have been linked to multiple inflammatory diseases, including psoriatic arthritis (PsA) and ankylosing spondylitis. This systematic review explored the effect of IL-12 and/or IL-23 inhibitors on the aetiology of axial PsA (axPsA) and axial spondyloarthritis (axSpA). We conducted a literature review of published articles up to June 2023. The outcomes assessed included Ankylosing Spondylitis Disease Activity Score, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), BASDAI-50, and modified BASDAI. Given the heterogeneity of study populations, designs, and outcome measures of the included studies, we performed a narrative synthesis. The data from the limited literature did not find any efficacy of IL-12 and/or IL-23 inhibitors for the management of axSpA, except for one observational study. However, reported data showed improvements in BASDAI, modified BASDAI, and Ankylosing Spondylitis Disease Activity Score for patients with axPsA. Limited and heterogeneous data currently leaves the effectiveness of IL-12 and/or IL-23 inhibitors for axSpA inconclusive. Yet, improvements in disease activity scores for patients with axPsA hint at the potential of IL-12 and/or IL-23 inhibitors in managing this condition. More extensive studies with larger samples are needed to definitively confirm the role of IL-12 and/or IL-23 inhibitors in axSpA and PsA.